Respiratory Strategic Roundup: Clinical Differentiation | Oct 7–Nov 11, 2026

This Respiratory Strategic Roundup examines how COPD exacerbation prevention, DPP1 inhibition and emerging respiratory biologics could influence competitive positioning. It explores the implications of late-stage clinical programs, bronchiectasis commercialization, IPF trial outcomes, RSV development and respiratory diagnostics for treatment differentiation and future commercial strategies.

Coverage Period: October 08 – November 11, 2026

Introduction

The defining story of this reporting period is the growing competition to reduce respiratory exacerbations through targeted anti-inflammatory therapies, supported by expanding commercialization, late-stage clinical development and investment in differentiated mechanisms.

This shift was evident in COPD, bronchiectasis and asthma, where developers advanced treatments targeting neutrophilic inflammation, combined bronchodilation and anti-inflammatory activity, and upstream inflammatory pathways. Meanwhile, progress in RSV antivirals and respiratory diagnostics highlighted the importance of patient selection and actionable clinical evidence. A failed IPF trial provided a reminder that biological rationale alone does not guarantee therapeutic benefit. Respiratory competition is therefore moving beyond novel mechanisms toward demonstrating meaningful clinical outcomes, establishing treatment positioning and translating innovation into commercial adoption.

Companies covered: Merck & Co. (MSD), Boehringer Ingelheim, Insmed, Windward Bio, Syndax Pharmaceuticals, Enanta Pharmaceuticals, Roche

Clinical areas covered: Chronic obstructive pulmonary disease (COPD), Bronchiectasis, Severe asthma, Idiopathic pulmonary fibrosis (IPF), Respiratory syncytial virus (RSV) infection, Respiratory diagnostics

Executive Summary

• COPD competition is intensifying around exacerbation prevention. Merck’s Phase 3 ENHANCE-3 trial of ensifentrine and Boehringer Ingelheim’s Phase 3 AIRWARD program for verducatib are evaluating different approaches to reducing exacerbations despite standard-of-care treatment. Their outcomes could influence how emerging therapies are positioned within established COPD management.
• DPP1 inhibition is progressing from bronchiectasis commercialization toward broader respiratory development. Insmed’s launch of BRINSUPRI in Japan establishes another commercial market for neutrophil-targeted treatment. Boehringer Ingelheim’s development of verducatib across bronchiectasis and COPD will test whether the mechanism can deliver benefits across distinct inflammatory airway diseases.
• Respiratory biologics are attracting investment as competition in inflammatory pathways expands. Windward Bio’s proposed IPO and its China-originated anti-TSLP and bispecific antibody programs demonstrate continued interest in differentiated respiratory immunology assets. Longer dosing intervals and multi-pathway targeting could provide competitive advantages, although clinical validation remains essential.
• Clinical evidence and patient selection are becoming critical determinants of development success. Syndax’s unsuccessful axatilimab Phase 2 trial in IPF highlights the limitations of mechanistic rationale without demonstrated efficacy. Enanta’s targeted RSV antiviral development and Roche’s expanded respiratory diagnostic capabilities reinforce the importance of identifying appropriate patients and generating clinically actionable evidence.

Watch the video summary

Strategic Perspective on Respiratory Therapeutics Developments

COPD Exacerbation Prevention Raises Competitive Stakes: Merck and Boehringer Ingelheim

Reducing exacerbations in patients already receiving established maintenance treatment is emerging as an important area of competition in COPD drug development.

Merck initiated the Phase 3 ENHANCE-3 trial of ensifentrine in approximately 2,136 patients with a history of exacerbations despite standard-of-care treatment. Although ensifentrine is approved in the United States for COPD maintenance treatment, ENHANCE-3 is designed to generate additional evidence on its ability to prevent exacerbations.

Boehringer Ingelheim registered the Phase 3 AIRWARD trial of verducatib, an oral DPP1 inhibitor, in approximately 1,800 patients with persistent exacerbations and blood eosinophil counts below 300 cells/µL. The program represents a targeted approach to neutrophil-associated inflammation.

The two programs pursue different therapeutic strategies. Ensifentrine combines bronchodilation and non-corticosteroid anti-inflammatory activity, while verducatib targets the activation of neutrophil serine proteases.

Their development reflects an opportunity to address residual exacerbation risk beyond existing inhaled treatment regimens. Demonstrating additional benefits could strengthen treatment differentiation and create new options for patients whose disease remains inadequately controlled.

For the COPD market, competition may increasingly depend on exacerbation reduction, inflammatory characteristics and compatibility with standard therapy rather than improvements in lung function alone.

The principal uncertainty is whether these approaches will deliver sufficiently meaningful benefits to influence treatment decisions. Their eventual positioning will depend on efficacy, safety, administration requirements and the strength of evidence supporting use alongside established therapies.

DPP1 Inhibition Tests Broader Market Potential: Insmed and Boehringer Ingelheim

DPP1 inhibition is becoming an established commercial approach in bronchiectasis while its potential across other respiratory diseases enters more advanced clinical testing.

Insmed launched BRINSUPRI (brensocatib) in Japan in October following approval based on the Phase 3 ASPEN study. The therapy became the first approved and commercially available treatment specifically for non-cystic fibrosis bronchiectasis in Japan, extending its presence across major international markets.

Brensocatib inhibits DPP1, reducing activation of neutrophil serine proteases implicated in chronic airway inflammation. Its approval provides clinical and regulatory validation for the mechanism in bronchiectasis.

Boehringer Ingelheim is pursuing the same pathway through verducatib, which is being investigated in Phase 3 studies for both bronchiectasis and COPD. The COPD program will test whether targeting neutrophil-driven inflammation can provide meaningful benefits in another major airway disease.

The commercial implications extend beyond individual assets. DPP1 inhibition could become a mechanism supporting respiratory franchises across multiple indications, creating opportunities for portfolio development and differentiated treatment positioning.

However, commercial success will require more than regulatory approval. Patient identification, physician adoption, reimbursement, tolerability and sustained treatment use will shape uptake across markets.

The main uncertainty is whether efficacy established in bronchiectasis can translate into COPD, where underlying disease biology and treatment pathways differ. Clinical results from verducatib’s programs will be important in determining whether DPP1 inhibition can support broader respiratory use.

Respiratory Biologics Face Differentiation Challenges: Windward Bio

Investment in targeted respiratory biologics continues as companies seek differentiation within increasingly competitive inflammatory treatment pathways.

Windward Bio’s proposed Nasdaq IPO aims to raise approximately $204 million in net proceeds at the midpoint of its proposed pricing range. The financing is intended to support development of respiratory assets licensed from Chinese biotechnology companies, including WIN378, an anti-TSLP monoclonal antibody, and WIN027, a bispecific antibody targeting TSLP and IL-13.

WIN378 is being evaluated in asthma and COPD, while WIN027 is being developed for respiratory and inflammatory indications. Sanofi’s agreement to purchase $50 million in Windward shares through a concurrent private placement further reflects interest in the company’s pipeline.

TSLP has already been clinically validated as a therapeutic target in severe asthma. Consequently, emerging programs must establish advantages beyond targeting the same inflammatory pathway.

Potential differentiation could come from extended dosing intervals, broader pathway inhibition or efficacy across distinct patient populations. Bispecific approaches may also offer opportunities to address multiple inflammatory mechanisms through a single therapy.

The market implication is an increasingly demanding competitive environment in which clinical performance, treatment convenience and development execution will determine positioning. Cross-border licensing may also remain an important strategy for accessing differentiated biologic assets.

Significant uncertainty remains regarding the proposed financing and clinical development outcomes. Longer dosing intervals and dual-pathway targeting offer potential advantages, but meaningful efficacy, safety and durability must still be demonstrated.

Clinical Evidence Shapes Development Decisions: Syndax, Enanta and Roche

Developments in pulmonary fibrosis, respiratory infections and diagnostics highlight the importance of aligning therapeutic mechanisms with clinically meaningful outcomes.

Syndax reported that its Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis failed to meet the primary endpoint of annualized forced vital capacity decline. Despite a safety profile comparable to placebo, the company decided not to pursue further development in IPF.

The outcome illustrates the challenges of translating a plausible anti-inflammatory or antifibrotic mechanism into measurable disease benefit.

In respiratory infections, Enanta initiated the Phase 2b/3 RESOLVE trial of zelicapavir in adults at high risk of severe RSV outcomes, including patients with COPD, congestive heart failure or advanced age. The trial will evaluate symptom resolution and hospitalization outcomes, building on earlier clinical signals in selected high-risk patients.

Roche also received FDA clearance for its cobas eplex respiratory pathogen panel 3, which supports flexible testing for multiple respiratory pathogens. Such diagnostic capabilities may help clinicians identify infections and guide management decisions.

These developments reinforce the value of patient selection, relevant clinical endpoints and diagnostic precision. For developers, clearly establishing who benefits and how outcomes improve may be as important as demonstrating a new mechanism.

The uncertainty lies in clinical translation. Zelicapavir’s earlier findings require confirmation, while the practical impact of expanded diagnostic testing will depend on implementation and demonstrated improvements in patient management.

What We Are Watching Next in Respiratory Drug Development

• Merck’s ENHANCE-3 and Boehringer Ingelheim’s AIRWARD Phase 3 programs will provide important evidence on whether newer COPD therapies can reduce exacerbations beyond standard-of-care treatment.
• BRINSUPRI’s commercialization in Japan and other approved markets will help establish the adoption potential of DPP1 inhibition in bronchiectasis and the importance of regional reimbursement and prescribing practices.
• Verducatib’s development across COPD and bronchiectasis will test whether neutrophil-targeted therapy can achieve meaningful benefits across different respiratory indications.
• Windward Bio’s proposed IPO and progression of its anti-TSLP and bispecific antibody programs will indicate how financing and clinical differentiation are evolving in respiratory immunology.
• Enanta’s anticipated 2027 Phase 2b zelicapavir data will provide an important test of whether earlier symptom-resolution and hospitalization signals can be reproduced in high-risk RSV patients.

Key Takeaway: Clinical Evidence Drives Respiratory Differentiation

Respiratory competition is becoming more closely tied to the ability to demonstrate measurable clinical benefits in clearly defined patient populations. During this reporting period, COPD developers advanced exacerbation-prevention strategies, DPP1 inhibition expanded commercially in bronchiectasis, and investment continued in differentiated respiratory biologics.

These developments do not establish that emerging mechanisms will displace existing therapies. They do indicate that future competitive positioning may depend on showing meaningful benefits beyond standard treatment, identifying patients most likely to respond and translating clinical evidence into routine use.

The next phase of respiratory market development will be shaped by which approaches can convert scientific differentiation into validated outcomes and sustainable commercial adoption.

🌐 Explore LucidQuest Strategic Roundups across multiple therapy areas for deeper healthcare and pharma analysis